<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950933</url>
  </required_header>
  <id_info>
    <org_study_id>D2020076</org_study_id>
    <nct_id>NCT04950933</nct_id>
  </id_info>
  <brief_title>The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Positives Parallel Controlled, Phase Ⅱ Clinical Trial to Evaluate the Efficacy and Safety of Huollingshengji Granules in the Treatment of Amyotrophic Lateral Sclerosis (Spleen qi Deficiency, Kidney Yang Deficiency Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to evaluate the efficacy and safety of Dong Lingsheng Ji Granule in the&#xD;
      treatment of amyotrophic lateral sclerosis (spleen deficiency, kidney-yang deficiency&#xD;
      syndrome) in comparison with riluzole, so as to provide data support for marketing&#xD;
      application or subsequent clinical research design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposed the multicenter, randomized, double-blind, double simulation, positive&#xD;
      drug parallel contrast the bad effect of experimental design, into the treatment group 72&#xD;
      cases, control group of 72 cases with the azole comparison, evaluation Dong Ling raw grain&#xD;
      treatment on muscle atrophy amyotrophic lateral sclerosis (lack of temper, kidney Yang&#xD;
      deficiency syndrome) efficacy and safety, for applications or follow-up clinical study design&#xD;
      to provide data support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R scores</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in ALSFRS-R scores from baseline after 48 weeks of treatment, The ALSFRS-R scale (ALS Functional Rating Scale) includes 12 items including medulla oblongata function, limb function and respiratory function, with a total score of 48. The lower the score, the more serious the neurological function damage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FVC%</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in FVC% from baseline after 48 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huolingshengji Granules</intervention_name>
    <description>1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole tablet</intervention_name>
    <description>Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the Western diagnostic criteria for amyotrophic lateral sclerosis (ALS)&#xD;
             (clinically confirmed ALS, clinically likely ALS or clinically likely ALS- laboratory&#xD;
             support);&#xD;
&#xD;
          2. The score of the modified amyotrophic lateral sclerosis function scale (ALSFRS-R) was&#xD;
             ≥2 points for each item (among which dyspnea, sitting breathing and respiratory&#xD;
             insufficiency were all 4 points);&#xD;
&#xD;
          3. The percentage of forced vital capacity in the predicted value (FVC%) ≥70%;&#xD;
&#xD;
          4. the duration of the disease is 3 years or less (from the first onset of any symptoms&#xD;
             of ALS);&#xD;
&#xD;
          5. TCM syndrome differentiation for deficiency of temper, kidney Yang deficiency&#xD;
             syndrome;&#xD;
&#xD;
          6. Age 45-70 (including 45 and 70), gender unlimited;&#xD;
&#xD;
          7. Voluntarily participate in the clinical trial, give informed consent and sign informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:(1) Patients diagnosed with familial ALS; (2) Those who have undergone&#xD;
        gastrostomy; (3) patients with other neurological diseases similar to ALS, such as cervical&#xD;
        spondylotic myelopathy, lumbar spondylopathy, dementia, etc., which may affect the&#xD;
        evaluation of drug effectiveness; (4) electromyogram detection found motor nerve conduction&#xD;
        block, sensory nerve conduction abnormality, imaging examination (CT or MRI) found that can&#xD;
        explain the clinical manifestations of substantial lesions; (5) Patients who had been&#xD;
        treated with riluzole or edaravone within 3 months before enrollment; (6) patients with a&#xD;
        history of spinal surgery after the onset of ALS; (7) aspartate aminotransferase (AST) or&#xD;
        alanine aminotransferase (ALT) &amp;gt; 1.5 times the upper limit of the normal reference&#xD;
        value, or blood muscle (SCR) &gt;; Upper limit of normal reference value; (8) Patients with&#xD;
        other serious primary diseases of the nervous system, heart, lung, hematopoietic system or&#xD;
        endocrine system and psychosis; (9) Suspected or have a history of alcohol and drug abuse;&#xD;
        (10) Pregnant women or lactating women, subjects of reproductive age (including male&#xD;
        subjects with heterosexual behavior and their female partners with fertility potential)&#xD;
        have pregnancy plans or are unwilling to take effective contraceptive measures within 3&#xD;
        months from the beginning of screening to the end of drug withdrawal; (11) People who are&#xD;
        known or suspected to have a history of allergy to the test drug and its excipients; (12)&#xD;
        Screening participants who had participated in other clinical trials within the previous 3&#xD;
        months; (13) Those considered by the researcher to be unsuitable to participate in this&#xD;
        clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongsheng Fan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongsheng Fan</last_name>
    <phone>+86 13701023871</phone>
    <email>dsfan@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongsheng Fan</last_name>
      <phone>13701023871</phone>
      <email>dsfan@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

